nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Glucosamine—TNF—psoriatic arthritis	0.0288	1	CrCbGaD
Vidarabine—Intracranial pressure increased—Prednisolone—psoriatic arthritis	0.0236	0.0243	CcSEcCtD
Vidarabine—Intracranial pressure increased—Triamcinolone—psoriatic arthritis	0.0217	0.0223	CcSEcCtD
Vidarabine—Intracranial pressure increased—Methylprednisolone—psoriatic arthritis	0.0216	0.0223	CcSEcCtD
Vidarabine—Intracranial pressure increased—Dexamethasone—psoriatic arthritis	0.0197	0.0203	CcSEcCtD
Vidarabine—Intracranial pressure increased—Betamethasone—psoriatic arthritis	0.0197	0.0203	CcSEcCtD
Vidarabine—Taste metallic—Methotrexate—psoriatic arthritis	0.0188	0.0194	CcSEcCtD
Vidarabine—Intracranial pressure increased—Prednisone—psoriatic arthritis	0.0171	0.0176	CcSEcCtD
Vidarabine—Dysgeusia—Auranofin—psoriatic arthritis	0.0132	0.0136	CcSEcCtD
Vidarabine—Angioedema—Auranofin—psoriatic arthritis	0.0123	0.0127	CcSEcCtD
Vidarabine—Tingling sensation—Methylprednisolone—psoriatic arthritis	0.0112	0.0116	CcSEcCtD
Vidarabine—Tingling sensation—Betamethasone—psoriatic arthritis	0.0102	0.0105	CcSEcCtD
Vidarabine—Tingling sensation—Dexamethasone—psoriatic arthritis	0.0102	0.0105	CcSEcCtD
Vidarabine—Urticaria—Auranofin—psoriatic arthritis	0.00876	0.00902	CcSEcCtD
Vidarabine—Burning sensation—Methotrexate—psoriatic arthritis	0.00861	0.00887	CcSEcCtD
Vidarabine—Apnoea—Methotrexate—psoriatic arthritis	0.00706	0.00727	CcSEcCtD
Vidarabine—Affect lability—Prednisolone—psoriatic arthritis	0.00704	0.00725	CcSEcCtD
Vidarabine—Vomiting—Auranofin—psoriatic arthritis	0.00701	0.00722	CcSEcCtD
Vidarabine—Rash—Auranofin—psoriatic arthritis	0.00695	0.00716	CcSEcCtD
Vidarabine—Dermatitis—Auranofin—psoriatic arthritis	0.00694	0.00715	CcSEcCtD
Vidarabine—Cardiac arrest—Prednisolone—psoriatic arthritis	0.0068	0.007	CcSEcCtD
Vidarabine—Mood swings—Prednisolone—psoriatic arthritis	0.00678	0.00698	CcSEcCtD
Vidarabine—Cardiac failure—Methylprednisolone—psoriatic arthritis	0.00672	0.00692	CcSEcCtD
Vidarabine—Nausea—Auranofin—psoriatic arthritis	0.00655	0.00674	CcSEcCtD
Vidarabine—Affect lability—Triamcinolone—psoriatic arthritis	0.00647	0.00667	CcSEcCtD
Vidarabine—Affect lability—Methylprednisolone—psoriatic arthritis	0.00646	0.00665	CcSEcCtD
Vidarabine—Cardiac arrest—Triamcinolone—psoriatic arthritis	0.00625	0.00644	CcSEcCtD
Vidarabine—Cardiac arrest—Methylprednisolone—psoriatic arthritis	0.00624	0.00643	CcSEcCtD
Vidarabine—Mood swings—Triamcinolone—psoriatic arthritis	0.00623	0.00642	CcSEcCtD
Vidarabine—Mood swings—Methylprednisolone—psoriatic arthritis	0.00622	0.0064	CcSEcCtD
Vidarabine—Cardiac failure—Dexamethasone—psoriatic arthritis	0.00611	0.0063	CcSEcCtD
Vidarabine—Cardiac failure—Betamethasone—psoriatic arthritis	0.00611	0.0063	CcSEcCtD
Vidarabine—Respiratory failure—Methotrexate—psoriatic arthritis	0.00609	0.00627	CcSEcCtD
Vidarabine—Affect lability—Dexamethasone—psoriatic arthritis	0.00587	0.00605	CcSEcCtD
Vidarabine—Affect lability—Betamethasone—psoriatic arthritis	0.00587	0.00605	CcSEcCtD
Vidarabine—Cardiac arrest—Betamethasone—psoriatic arthritis	0.00567	0.00584	CcSEcCtD
Vidarabine—Cardiac arrest—Dexamethasone—psoriatic arthritis	0.00567	0.00584	CcSEcCtD
Vidarabine—Mood swings—Betamethasone—psoriatic arthritis	0.00565	0.00582	CcSEcCtD
Vidarabine—Mood swings—Dexamethasone—psoriatic arthritis	0.00565	0.00582	CcSEcCtD
Vidarabine—Bronchospasm—Methylprednisolone—psoriatic arthritis	0.00558	0.00574	CcSEcCtD
Vidarabine—Acute coronary syndrome—Prednisolone—psoriatic arthritis	0.00543	0.00559	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisolone—psoriatic arthritis	0.0054	0.00556	CcSEcCtD
Vidarabine—Cardiac failure—Prednisone—psoriatic arthritis	0.00533	0.00548	CcSEcCtD
Vidarabine—Affect lability—Prednisone—psoriatic arthritis	0.00512	0.00527	CcSEcCtD
Vidarabine—Bradycardia—Prednisolone—psoriatic arthritis	0.00504	0.00519	CcSEcCtD
Vidarabine—Acute coronary syndrome—Triamcinolone—psoriatic arthritis	0.005	0.00514	CcSEcCtD
Vidarabine—Acute coronary syndrome—Methylprednisolone—psoriatic arthritis	0.00499	0.00513	CcSEcCtD
Vidarabine—Myocardial infarction—Triamcinolone—psoriatic arthritis	0.00497	0.00512	CcSEcCtD
Vidarabine—Myocardial infarction—Methylprednisolone—psoriatic arthritis	0.00496	0.0051	CcSEcCtD
Vidarabine—Cardiac arrest—Prednisone—psoriatic arthritis	0.00494	0.00509	CcSEcCtD
Vidarabine—Mood swings—Prednisone—psoriatic arthritis	0.00492	0.00507	CcSEcCtD
Vidarabine—Sweating—Methylprednisolone—psoriatic arthritis	0.00485	0.00499	CcSEcCtD
Vidarabine—Bradycardia—Triamcinolone—psoriatic arthritis	0.00463	0.00477	CcSEcCtD
Vidarabine—Bradycardia—Methylprednisolone—psoriatic arthritis	0.00462	0.00476	CcSEcCtD
Vidarabine—Acute coronary syndrome—Betamethasone—psoriatic arthritis	0.00453	0.00467	CcSEcCtD
Vidarabine—Acute coronary syndrome—Dexamethasone—psoriatic arthritis	0.00453	0.00467	CcSEcCtD
Vidarabine—Myocardial infarction—Betamethasone—psoriatic arthritis	0.00451	0.00464	CcSEcCtD
Vidarabine—Myocardial infarction—Dexamethasone—psoriatic arthritis	0.00451	0.00464	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—psoriatic arthritis	0.00443	0.00456	CcSEcCtD
Vidarabine—Arrhythmia—Prednisolone—psoriatic arthritis	0.00442	0.00455	CcSEcCtD
Vidarabine—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.00421	0.00434	CcSEcCtD
Vidarabine—Bradycardia—Betamethasone—psoriatic arthritis	0.0042	0.00433	CcSEcCtD
Vidarabine—Bradycardia—Dexamethasone—psoriatic arthritis	0.0042	0.00433	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—psoriatic arthritis	0.00411	0.00424	CcSEcCtD
Vidarabine—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00409	0.00421	CcSEcCtD
Vidarabine—Arrhythmia—Triamcinolone—psoriatic arthritis	0.00406	0.00419	CcSEcCtD
Vidarabine—Vision blurred—Prednisolone—psoriatic arthritis	0.00406	0.00418	CcSEcCtD
Vidarabine—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.00406	0.00418	CcSEcCtD
Vidarabine—Acute coronary syndrome—Prednisone—psoriatic arthritis	0.00395	0.00407	CcSEcCtD
Vidarabine—Angioedema—Prednisolone—psoriatic arthritis	0.00394	0.00405	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisone—psoriatic arthritis	0.00393	0.00404	CcSEcCtD
Vidarabine—Dysgeusia—Triamcinolone—psoriatic arthritis	0.00388	0.00399	CcSEcCtD
Vidarabine—Syncope—Prednisolone—psoriatic arthritis	0.00386	0.00398	CcSEcCtD
Vidarabine—Back pain—Triamcinolone—psoriatic arthritis	0.00383	0.00395	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisolone—psoriatic arthritis	0.00379	0.0039	CcSEcCtD
Vidarabine—Convulsion—Prednisolone—psoriatic arthritis	0.00373	0.00384	CcSEcCtD
Vidarabine—Hypertension—Prednisolone—psoriatic arthritis	0.00372	0.00383	CcSEcCtD
Vidarabine—Arrhythmia—Betamethasone—psoriatic arthritis	0.00369	0.0038	CcSEcCtD
Vidarabine—Arrhythmia—Dexamethasone—psoriatic arthritis	0.00369	0.0038	CcSEcCtD
Vidarabine—Bradycardia—Prednisone—psoriatic arthritis	0.00366	0.00377	CcSEcCtD
Vidarabine—Discomfort—Prednisolone—psoriatic arthritis	0.00362	0.00373	CcSEcCtD
Vidarabine—Angioedema—Triamcinolone—psoriatic arthritis	0.00362	0.00373	CcSEcCtD
Vidarabine—Angioedema—Methylprednisolone—psoriatic arthritis	0.00361	0.00372	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.0036	0.00371	CcSEcCtD
Vidarabine—Syncope—Triamcinolone—psoriatic arthritis	0.00355	0.00366	CcSEcCtD
Vidarabine—Syncope—Methylprednisolone—psoriatic arthritis	0.00354	0.00365	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00352	0.00362	CcSEcCtD
Vidarabine—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.00348	0.00358	CcSEcCtD
Vidarabine—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.00347	0.00358	CcSEcCtD
Vidarabine—Shock—Prednisolone—psoriatic arthritis	0.00346	0.00356	CcSEcCtD
Vidarabine—Cough—Triamcinolone—psoriatic arthritis	0.00346	0.00356	CcSEcCtD
Vidarabine—Convulsion—Triamcinolone—psoriatic arthritis	0.00343	0.00353	CcSEcCtD
Vidarabine—Tachycardia—Prednisolone—psoriatic arthritis	0.00343	0.00353	CcSEcCtD
Vidarabine—Convulsion—Methylprednisolone—psoriatic arthritis	0.00342	0.00353	CcSEcCtD
Vidarabine—Hypertension—Triamcinolone—psoriatic arthritis	0.00342	0.00352	CcSEcCtD
Vidarabine—Hypertension—Methylprednisolone—psoriatic arthritis	0.00341	0.00351	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.0034	0.0035	CcSEcCtD
Vidarabine—Anxiety—Methylprednisolone—psoriatic arthritis	0.00335	0.00345	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—psoriatic arthritis	0.00335	0.00345	CcSEcCtD
Vidarabine—Flushing—Prednisone—psoriatic arthritis	0.00334	0.00344	CcSEcCtD
Vidarabine—Discomfort—Triamcinolone—psoriatic arthritis	0.00333	0.00343	CcSEcCtD
Vidarabine—Discomfort—Methylprednisolone—psoriatic arthritis	0.00332	0.00342	CcSEcCtD
Vidarabine—Dry mouth—Triamcinolone—psoriatic arthritis	0.0033	0.0034	CcSEcCtD
Vidarabine—Angioedema—Betamethasone—psoriatic arthritis	0.00328	0.00338	CcSEcCtD
Vidarabine—Angioedema—Dexamethasone—psoriatic arthritis	0.00328	0.00338	CcSEcCtD
Vidarabine—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00323	0.00333	CcSEcCtD
Vidarabine—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00323	0.00332	CcSEcCtD
Vidarabine—Syncope—Dexamethasone—psoriatic arthritis	0.00322	0.00332	CcSEcCtD
Vidarabine—Syncope—Betamethasone—psoriatic arthritis	0.00322	0.00332	CcSEcCtD
Vidarabine—Arrhythmia—Prednisone—psoriatic arthritis	0.00321	0.00331	CcSEcCtD
Vidarabine—Sweating—Methotrexate—psoriatic arthritis	0.00321	0.0033	CcSEcCtD
Vidarabine—Shock—Triamcinolone—psoriatic arthritis	0.00318	0.00327	CcSEcCtD
Vidarabine—Shock—Methylprednisolone—psoriatic arthritis	0.00317	0.00327	CcSEcCtD
Vidarabine—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.00316	0.00325	CcSEcCtD
Vidarabine—Loss of consciousness—Betamethasone—psoriatic arthritis	0.00316	0.00325	CcSEcCtD
Vidarabine—Paraesthesia—Prednisolone—psoriatic arthritis	0.00316	0.00325	CcSEcCtD
Vidarabine—Tachycardia—Triamcinolone—psoriatic arthritis	0.00315	0.00325	CcSEcCtD
Vidarabine—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00315	0.00324	CcSEcCtD
Vidarabine—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00313	0.00322	CcSEcCtD
Vidarabine—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00312	0.00321	CcSEcCtD
Vidarabine—Convulsion—Dexamethasone—psoriatic arthritis	0.00311	0.00321	CcSEcCtD
Vidarabine—Convulsion—Betamethasone—psoriatic arthritis	0.00311	0.00321	CcSEcCtD
Vidarabine—Hypertension—Dexamethasone—psoriatic arthritis	0.0031	0.00319	CcSEcCtD
Vidarabine—Hypertension—Betamethasone—psoriatic arthritis	0.0031	0.00319	CcSEcCtD
Vidarabine—Anxiety—Dexamethasone—psoriatic arthritis	0.00305	0.00314	CcSEcCtD
Vidarabine—Anxiety—Betamethasone—psoriatic arthritis	0.00305	0.00314	CcSEcCtD
Vidarabine—Discomfort—Betamethasone—psoriatic arthritis	0.00302	0.00311	CcSEcCtD
Vidarabine—Discomfort—Dexamethasone—psoriatic arthritis	0.00302	0.00311	CcSEcCtD
Vidarabine—Hypotension—Methylprednisolone—psoriatic arthritis	0.00301	0.0031	CcSEcCtD
Vidarabine—Pain—Prednisolone—psoriatic arthritis	0.00301	0.0031	CcSEcCtD
Vidarabine—Vision blurred—Prednisone—psoriatic arthritis	0.00295	0.00304	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00295	0.00303	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00294	0.00303	CcSEcCtD
Vidarabine—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.00293	0.00302	CcSEcCtD
Vidarabine—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.00293	0.00302	CcSEcCtD
Vidarabine—Paraesthesia—Triamcinolone—psoriatic arthritis	0.0029	0.00299	CcSEcCtD
Vidarabine—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.0029	0.00298	CcSEcCtD
Vidarabine—Shock—Dexamethasone—psoriatic arthritis	0.00289	0.00297	CcSEcCtD
Vidarabine—Shock—Betamethasone—psoriatic arthritis	0.00289	0.00297	CcSEcCtD
Vidarabine—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00288	0.00297	CcSEcCtD
Vidarabine—Agitation—Prednisone—psoriatic arthritis	0.00288	0.00296	CcSEcCtD
Vidarabine—Tachycardia—Dexamethasone—psoriatic arthritis	0.00286	0.00295	CcSEcCtD
Vidarabine—Tachycardia—Betamethasone—psoriatic arthritis	0.00286	0.00295	CcSEcCtD
Vidarabine—Angioedema—Prednisone—psoriatic arthritis	0.00286	0.00294	CcSEcCtD
Vidarabine—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00284	0.00292	CcSEcCtD
Vidarabine—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00284	0.00292	CcSEcCtD
Vidarabine—Syncope—Prednisone—psoriatic arthritis	0.00281	0.00289	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—psoriatic arthritis	0.0028	0.00288	CcSEcCtD
Vidarabine—Urticaria—Prednisolone—psoriatic arthritis	0.00279	0.00288	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—psoriatic arthritis	0.00279	0.00287	CcSEcCtD
Vidarabine—Pain—Triamcinolone—psoriatic arthritis	0.00276	0.00285	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisone—psoriatic arthritis	0.00275	0.00283	CcSEcCtD
Vidarabine—Hypotension—Betamethasone—psoriatic arthritis	0.00274	0.00282	CcSEcCtD
Vidarabine—Hypotension—Dexamethasone—psoriatic arthritis	0.00274	0.00282	CcSEcCtD
Vidarabine—Convulsion—Prednisone—psoriatic arthritis	0.00271	0.00279	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00271	0.00279	CcSEcCtD
Vidarabine—Hypertension—Prednisone—psoriatic arthritis	0.0027	0.00278	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00267	0.00275	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00267	0.00275	CcSEcCtD
Vidarabine—Anxiety—Prednisone—psoriatic arthritis	0.00266	0.00273	CcSEcCtD
Vidarabine—Paraesthesia—Betamethasone—psoriatic arthritis	0.00263	0.00271	CcSEcCtD
Vidarabine—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00263	0.00271	CcSEcCtD
Vidarabine—Discomfort—Prednisone—psoriatic arthritis	0.00263	0.00271	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00259	0.00267	CcSEcCtD
Vidarabine—Urticaria—Triamcinolone—psoriatic arthritis	0.00257	0.00264	CcSEcCtD
Vidarabine—Urticaria—Methylprednisolone—psoriatic arthritis	0.00256	0.00264	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—psoriatic arthritis	0.00256	0.00264	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisone—psoriatic arthritis	0.00255	0.00263	CcSEcCtD
Vidarabine—Back pain—Methotrexate—psoriatic arthritis	0.00253	0.00261	CcSEcCtD
Vidarabine—Shock—Prednisone—psoriatic arthritis	0.00251	0.00259	CcSEcCtD
Vidarabine—Pain—Betamethasone—psoriatic arthritis	0.00251	0.00258	CcSEcCtD
Vidarabine—Pain—Dexamethasone—psoriatic arthritis	0.00251	0.00258	CcSEcCtD
Vidarabine—Tachycardia—Prednisone—psoriatic arthritis	0.00249	0.00257	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00247	0.00254	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—psoriatic arthritis	0.00247	0.00254	CcSEcCtD
Vidarabine—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00238	0.00245	CcSEcCtD
Vidarabine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00238	0.00245	CcSEcCtD
Vidarabine—Urticaria—Betamethasone—psoriatic arthritis	0.00233	0.0024	CcSEcCtD
Vidarabine—Urticaria—Dexamethasone—psoriatic arthritis	0.00233	0.0024	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.00233	0.0024	CcSEcCtD
Vidarabine—Dizziness—Prednisolone—psoriatic arthritis	0.00232	0.00239	CcSEcCtD
Vidarabine—Asthenia—Triamcinolone—psoriatic arthritis	0.00232	0.00239	CcSEcCtD
Vidarabine—Asthenia—Methylprednisolone—psoriatic arthritis	0.00231	0.00238	CcSEcCtD
Vidarabine—Paraesthesia—Prednisone—psoriatic arthritis	0.00229	0.00236	CcSEcCtD
Vidarabine—Cough—Methotrexate—psoriatic arthritis	0.00228	0.00235	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—psoriatic arthritis	0.00227	0.00233	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—psoriatic arthritis	0.00223	0.00229	CcSEcCtD
Vidarabine—Rash—Prednisolone—psoriatic arthritis	0.00222	0.00228	CcSEcCtD
Vidarabine—Dermatitis—Prednisolone—psoriatic arthritis	0.00221	0.00228	CcSEcCtD
Vidarabine—Headache—Prednisolone—psoriatic arthritis	0.0022	0.00227	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—psoriatic arthritis	0.0022	0.00227	CcSEcCtD
Vidarabine—Dizziness—Triamcinolone—psoriatic arthritis	0.00214	0.0022	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00213	0.0022	CcSEcCtD
Vidarabine—Dizziness—Methylprednisolone—psoriatic arthritis	0.00213	0.0022	CcSEcCtD
Vidarabine—Asthenia—Dexamethasone—psoriatic arthritis	0.0021	0.00217	CcSEcCtD
Vidarabine—Asthenia—Betamethasone—psoriatic arthritis	0.0021	0.00217	CcSEcCtD
Vidarabine—Nausea—Prednisolone—psoriatic arthritis	0.00209	0.00215	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00206	0.00212	CcSEcCtD
Vidarabine—Vomiting—Triamcinolone—psoriatic arthritis	0.00206	0.00212	CcSEcCtD
Vidarabine—Vomiting—Methylprednisolone—psoriatic arthritis	0.00205	0.00211	CcSEcCtD
Vidarabine—Rash—Triamcinolone—psoriatic arthritis	0.00204	0.0021	CcSEcCtD
Vidarabine—Dermatitis—Triamcinolone—psoriatic arthritis	0.00204	0.0021	CcSEcCtD
Vidarabine—Rash—Methylprednisolone—psoriatic arthritis	0.00203	0.00209	CcSEcCtD
Vidarabine—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00203	0.00209	CcSEcCtD
Vidarabine—Urticaria—Prednisone—psoriatic arthritis	0.00203	0.00209	CcSEcCtD
Vidarabine—Headache—Triamcinolone—psoriatic arthritis	0.00203	0.00209	CcSEcCtD
Vidarabine—Headache—Methylprednisolone—psoriatic arthritis	0.00202	0.00208	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—psoriatic arthritis	0.00199	0.00205	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.00194	0.002	CcSEcCtD
Vidarabine—Dizziness—Betamethasone—psoriatic arthritis	0.00194	0.002	CcSEcCtD
Vidarabine—Dizziness—Dexamethasone—psoriatic arthritis	0.00194	0.002	CcSEcCtD
Vidarabine—Nausea—Triamcinolone—psoriatic arthritis	0.00192	0.00198	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—psoriatic arthritis	0.00192	0.00197	CcSEcCtD
Vidarabine—Nausea—Methylprednisolone—psoriatic arthritis	0.00192	0.00197	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—psoriatic arthritis	0.0019	0.00196	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—psoriatic arthritis	0.0019	0.00195	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisone—psoriatic arthritis	0.00188	0.00194	CcSEcCtD
Vidarabine—Vomiting—Dexamethasone—psoriatic arthritis	0.00186	0.00192	CcSEcCtD
Vidarabine—Vomiting—Betamethasone—psoriatic arthritis	0.00186	0.00192	CcSEcCtD
Vidarabine—Rash—Dexamethasone—psoriatic arthritis	0.00185	0.0019	CcSEcCtD
Vidarabine—Rash—Betamethasone—psoriatic arthritis	0.00185	0.0019	CcSEcCtD
Vidarabine—Dermatitis—Betamethasone—psoriatic arthritis	0.00185	0.0019	CcSEcCtD
Vidarabine—Dermatitis—Dexamethasone—psoriatic arthritis	0.00185	0.0019	CcSEcCtD
Vidarabine—Headache—Betamethasone—psoriatic arthritis	0.00184	0.00189	CcSEcCtD
Vidarabine—Headache—Dexamethasone—psoriatic arthritis	0.00184	0.00189	CcSEcCtD
Vidarabine—Asthenia—Prednisone—psoriatic arthritis	0.00183	0.00189	CcSEcCtD
Vidarabine—Pain—Methotrexate—psoriatic arthritis	0.00183	0.00188	CcSEcCtD
Vidarabine—Nausea—Betamethasone—psoriatic arthritis	0.00174	0.00179	CcSEcCtD
Vidarabine—Nausea—Dexamethasone—psoriatic arthritis	0.00174	0.00179	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—psoriatic arthritis	0.0017	0.00175	CcSEcCtD
Vidarabine—Dizziness—Prednisone—psoriatic arthritis	0.00169	0.00174	CcSEcCtD
Vidarabine—Vomiting—Prednisone—psoriatic arthritis	0.00162	0.00167	CcSEcCtD
Vidarabine—Rash—Prednisone—psoriatic arthritis	0.00161	0.00166	CcSEcCtD
Vidarabine—Dermatitis—Prednisone—psoriatic arthritis	0.00161	0.00166	CcSEcCtD
Vidarabine—Headache—Prednisone—psoriatic arthritis	0.0016	0.00165	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00157	0.00162	CcSEcCtD
Vidarabine—Asthenia—Methotrexate—psoriatic arthritis	0.00153	0.00158	CcSEcCtD
Vidarabine—Nausea—Prednisone—psoriatic arthritis	0.00152	0.00156	CcSEcCtD
Vidarabine—Dizziness—Methotrexate—psoriatic arthritis	0.00141	0.00145	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—psoriatic arthritis	0.00136	0.0014	CcSEcCtD
Vidarabine—Rash—Methotrexate—psoriatic arthritis	0.00135	0.00139	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—psoriatic arthritis	0.00134	0.00138	CcSEcCtD
Vidarabine—Headache—Methotrexate—psoriatic arthritis	0.00134	0.00138	CcSEcCtD
Vidarabine—Nausea—Methotrexate—psoriatic arthritis	0.00127	0.00131	CcSEcCtD
